Placebo IM 　 Pre-treatment  Post-treatment Pre-treatment Post-treatment Ulcers 0% 21% 0% 21% Mucosal breaks 0% 37% 16% 42% Denuded areas   5% 58% 5%  26%* Reddened folds 11% 42% 5%  10%* Red spots 58% 95% 63% 90% （* p<0.05 compared with Placebo at post-treatment, Chi-square test）

Table 1: Comparison of the control group and the irsogladine maleate (IM) group: Pre- and post-treatment incidence rates.